WuXi Biologics (Cayman) 대차 대조표 상태
재무 상태 기준 확인 5/6
WuXi Biologics (Cayman) 의 총 주주 지분은 CN¥44.6B 이고 총 부채는 CN¥2.2B, 이는 부채 대 자기자본 비율을 4.8% 로 가져옵니다. 총자산과 총부채는 각각 CN¥56.1B 및 CN¥11.5B 입니다. WuXi Biologics (Cayman) 의 EBIT는 CN¥3.5B 이며 이자보상배율은 -18.3 입니다. CN¥9.5B 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
4.8%
부채 비율
CN¥2.16b
부채
| 이자 보상 비율 | -18.3x |
| 현금 | CN¥9.53b |
| 주식 | CN¥44.64b |
| 총 부채 | CN¥11.46b |
| 총 자산 | CN¥56.11b |
최근 재무 상태 업데이트
WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet
Sep 12
Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly
Apr 15Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09Recent updates
After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar
Sep 26WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet
Sep 12Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why
Jun 12Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%
Jun 11Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding
Jun 11Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly
Apr 15Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge
Mar 04Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade
Dec 08Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Nov 10What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
Sep 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate
Aug 10Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?
Jun 19Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
May 12Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?
Mar 13Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?
Feb 13An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued
Jan 30Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching
Nov 20With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case
Nov 08Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?
Oct 27WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
Sep 08Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?
Aug 15재무 상태 분석
단기부채: 2269 의 단기 자산 ( CN¥19.8B )이 단기 부채( CN¥6.8B ).
장기 부채: 2269 의 단기 자산( CN¥19.8B )이 장기 부채( CN¥4.7B ).
부채 대 자본 내역 및 분석
부채 수준: 2269 총 부채보다 더 많은 현금을 보유하고 있습니다.
부채 감소: 2269 의 부채 대 자기자본 비율은 지난 5년간 0% 에서 4.8% 로 증가했습니다.
부채 범위: 2269 의 부채는 영업 현금 흐름 ( 149.3% )에 의해 잘 충당되었습니다.
이자 보장: 2269 지불하는 것보다 더 많은 이자를 벌기 때문에 이자 지불 보장은 문제가 되지 않습니다.